|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.080 USD | -2.26% |
|
-5.32% | -13.52% |
| 07-16 | Moderna advances its cancer therapy assessment, but the stock slides |  |
| 06-01 | Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies | CI |
Company Valuation: Immatics N.V.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 845.5 | 663.9 | 891.4 | 848.6 | 1,408 | 1,241 | - | - |
| Change | - | -21.47% | 34.26% | -4.8% | 65.88% | -11.84% | - | - |
| Enterprise Value (EV) 1 | 710 | 289.7 | 445.7 | 610.6 | 1,026 | 1,059 | 1,022 | 1,083 |
| Change | - | -59.19% | 53.83% | 36.99% | 68% | 3.2% | -3.49% | 5.98% |
| P/E | -8.25x | 14.7x | -8.08x | 47.1x | -5.61x | -4.43x | -4.83x | -5.43x |
| PBR | - | - | - | - | 2.51x | - | - | - |
| PEG | - | -0x | 0x | -0x | 0x | -0.47x | 0.58x | 0.5x |
| Capitalization / Revenue | 22.1x | 3.57x | 15.2x | 5.05x | 25.1x | 26.5x | 25.4x | 11x |
| EV / Revenue | 18.5x | 1.56x | 7.6x | 3.63x | 18.3x | 22.6x | 20.9x | 9.58x |
| EV / EBITDA | -7.96x | 7.29x | -4.34x | -21.5x | -5.2x | -3.8x | -3.31x | -3.13x |
| EV / EBIT | -7.47x | 8.99x | -4.04x | -14.7x | -4.85x | -3.53x | -3.27x | -3.52x |
| EV / FCF | -7.43x | - | -32.6x | -3.25x | -4.84x | -5.14x | -3.86x | -4.23x |
| FCF Yield | -13.5% | - | -3.06% | -30.8% | -20.7% | -19.5% | -25.9% | -23.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.63 | 0.592 | -1.303 | 0.151 | -1.872 | -2.05 | -1.879 | -1.671 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.29 | 186 | 58.62 | 168.1 | 56.13 | 46.86 | 48.87 | 113 |
| EBITDA 1 | -89.24 | 39.74 | -102.6 | -28.46 | -197.3 | -278.4 | -308.2 | -345.8 |
| EBIT 1 | -95.04 | 32.24 | -110.4 | -41.65 | -211.7 | -299.5 | -312.8 | -307.6 |
| Net income 1 | -102.8 | 40.38 | -105.3 | 16.41 | -228.5 | -276.9 | -277 | -265.5 |
| Net Debt 1 | -135.5 | -374.2 | -445.8 | -238.1 | -381.9 | -182.4 | -219.4 | -158.3 |
| Reference price 2 | 13.440 | 8.710 | 10.530 | 7.110 | 10.500 | 9.080 | 9.080 | 9.080 |
| Nbr of stocks (in thousands) | 62,909 | 76,227 | 84,656 | 119,356 | 134,064 | 136,673 | - | - |
| Announcement Date | 23/03/22 | 21/03/23 | 21/03/24 | 27/03/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.43x | 22.59x | -3.8x | -.--% | 1.24B | |
| 33.56x | 8.36x | 25.84x | 0.05% | 57.28B | |
| 20.68x | 6.37x | 13.94x | 1.54% | 54.99B | |
| -41.86x | 13.29x | -39.17x | -.--% | 23.18B | |
| -17.88x | 4.15x | -7.26x | -.--% | 22.59B | |
| 25.74x | 5.04x | 13.35x | -.--% | 20.46B | |
| 24.54x | 4.77x | 15.5x | -.--% | 17.56B | |
| -523.64x | 37.41x | -1539.29x | -.--% | 15.67B | |
| 43.58x | 17.61x | 45.34x | 0.08% | 14.46B | |
| 17.42x | 5.04x | 11.77x | -.--% | 13.92B | |
| Average | -42.23x | 12.46x | -146.38x | 0.17% | 24.13B | |
| Weighted average by Cap. | -19.45x | 9.76x | -89.42x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IMTX Stock
- Valuation Immatics N.V.
Select your edition
All financial news and data tailored to specific country editions
